Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fractyl Health
Fractyl Adds $100M Investment To Address Root Causes Of Type 2 Diabetes
The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.
Top 10 Start-Up Spotlight Stories In 2020: Theradaptive’s ‘Bone Paint,’ BioIntelliSense’s BioButton, Heart Tech, Portable Ultrasound, Digital Health
A look back at Medtech Insight’s 10 most-read Start-Up Spotlight stories in 2020 pointed to diverse interest among our readers focusing on orthopedics, innovations in cardiac surgery, portable ultrasound tech and digital tools for tracking vital signs and monitoring patients at home.
Start-Up Spotlight: Fractyl Attacks Insulin Resistance At Its Roots
The company is developing a novel duodenal mucosal resurfacing technology designed to reverse the metabolic process that causes insulin resistance in people with type 2 diabetes.
Fractyl's Novel Diabetes Treatment Clears First Hurdle In Clinical Trial
The first-in-human study of Fractyl's Revita duodenal mucosal resurfacing system shows significant short-term improvement in hyperglycemia in patients with type 2 diabetes, with few adverse events.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Fractyl Laboratories Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.